However, the relative inefficiency of anti‐tumor therapies based on systemic IFNα administration is thought to mainly reflect the relative inability of such therapies to target effective IFNα doses to cancer sites without reaching dose‐limiting toxicity (Link et al, 2005). Here, IFNA1 is linked to cancer.